John R. Traynor

Affiliations: 
University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Opiod signal transductions, addiction
Website:
http://sitemaker.umich.edu/traynor.lab/home
Google:
"John Traynor"
Mean distance: 13358.2
 
Cross-listing: MichiganTree

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Anand JP, Moore SC, Dixon EE, et al. (2024) Correction to "Structure-Activity Relationships of the Fentanyl Scaffold: Identification of Antagonists as Potential Opioid Overdose Reversal Agents". Acs Chemical Neuroscience. 15: 3587-3588
Demery-Poulos C, Moore SC, Levitt ES, et al. (2024) Xylazine Exacerbates Fentanyl-Induced Respiratory Depression and Bradycardia. Biorxiv : the Preprint Server For Biology
Anand JP, Moore SC, Dixon EE, et al. (2024) Structure-Activity Relationships of the Fentanyl Scaffold: Identification of Antagonists as Potential Opioid Overdose Reversal Agents. Acs Chemical Neuroscience
Olson KM, Devereaux AL, Chatterjee P, et al. (2023) Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy. Frontiers in Pharmacology. 14: 1230053
Chan WKB, Carlson HA, Traynor JR. (2023) . Molecular Pharmacology
Traynor JR, Moron JA. (2023) Opioid research in the time of the opioid crisis. British Journal of Pharmacology. 180: 793-796
Olson KM, Hillhouse TM, Burgess GE, et al. (2022) Delta opioid receptor-mediated antidepressant-like effects of diprenorphine in mice. The Journal of Pharmacology and Experimental Therapeutics
Disney A, Olson KM, Shafer AM, et al. (2022) Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose. Acs Chemical Neuroscience
Olson KM, Campbell A, Alt A, et al. (2022) Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands. Acs Pharmacology & Translational Science. 5: 694-709
Gerak LR, Maguire DR, Cami-Kobeci G, et al. (2022) OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects. Behavioural Pharmacology. 33: 377-394
See more...